Imaging Small-Cell Lung Cancer with Pentetreotide
Author Information
Author(s): K.J. O'Byrne, J.T. Ennis, P.J. Freyne, L.J. Clancy, J.S. Prichard, D.N. Carney
Primary Institution: Mater Misericordiae Hospital, Dublin, Ireland; St. James's Hospital, Dublin, Ireland
Hypothesis
The study evaluates the role of the radiolabelled somatostatin analogue, [I-111]pentetreotide, in detecting and staging small-cell lung cancer (SCLC) before and after chemotherapy.
Conclusion
[I-111]pentetreotide imaging may be useful in detecting residual intrathoracic disease in patients with SCLC who are thought to be in complete remission by conventional methods.
Supporting Evidence
- All primary sites of disease were detected by [I-111]pentetreotide imaging.
- Five of ten metastatic sites detected by standard staging were also imaged.
- A previously undetected cerebellar metastasis was found in one patient.
- [I-111]pentetreotide imaging detected residual intrathoracic disease in two patients thought to be in complete remission.
Takeaway
Doctors used a special imaging technique to find cancer in the lungs, and it helped them see some cancer spots that other tests missed.
Methodology
Thirteen patients with histologically proven SCLC were evaluated using scintigraphic imaging before and after chemotherapy.
Limitations
The study had a small sample size and may not represent all patients with SCLC.
Participant Demographics
The study included 13 patients, consisting of 3 women and 10 men, aged 29 to 68 years.
Want to read the original?
Access the complete publication on the publisher's website